Compare CSX Corporation (CSX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs GeneDx Holdings Corp — how do they compare? CSX Corporation trades at $47.21 (market cap $87.70B), while GeneDx Holdings Corp trades at $69.08 (market cap $2.02B). The key difference: CSX Corporation is far larger — about 43.4× GeneDx Holdings Corp's market cap, and CSX Corporation pays a 1.18% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and GeneDx Holdings Corp for 19 Days on average.
| CSX | WGS | |
|---|---|---|
Market Cap | $87.70B | $2.02B |
Volume | 6,980,781 | 734,640 |
Sector | Industrials | Health |
52-Week High | $53.21 | $167.51 |
52-Week Low | $33.68 | $34.51 |
Typical Hold Time | 55 Days | 19 Days |
Enterprise Value | $105.66B | $2.05B |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $46.81, down 1.45% with a bearish technical signal. The railroad operator shows mixed fundamentals with declining revenue from $14.9B in 2022 to $14.1B in 2025, though net income margins remain strong at 22.21%. Recent earnings show two beats and one miss, with Q3 2026 results pending. Analyst consensus is bullish with 59% buy ratings and a $51 price target, representing 9% upside from current levels.
CSX offers steady dividend income and pricing power in an irreplaceable freight network, but faces revenue pressure and elevated valuation multiples. The stock's investment case hinges on operational efficiency gains and freight volume recovery, balanced against economic sensitivity and competitive pressures in the transportation sector.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
